Halozyme therapeutics news
WebFeb 7, 2024 · At Halozyme, we are focused on new and proven therapeutic approaches. We are driven to bring innovative and disruptive solutions and support to partners with a … WebApr 10, 2024 · A high-level overview of Halozyme Therapeutics, Inc. (HALO) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools.
Halozyme therapeutics news
Did you know?
WebHalozyme provides disruptive drug delivery solutions with the goal of improving patient experiences and outcomes that can enhance the competitiveness of emerging and … WebMar 16, 2024 · In the last 3 months, 7 analysts have offered 12-month price targets for Halozyme Therapeutics. The company has an average price target of $57.86 with a high of $66.00 and a low of $42.00.
WebApr 6, 2024 · Halozyme Therapeutics has a news sentiment score of 0.67. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.40 average news sentiment score of Medical companies. WebThe patient is at the forefront of everything we do at Halozyme. With our disruptive drug delivery technologies and robust commercial portfolio, we are committed to reinventing …
WebHalozyme Therapeutics 12390 El Camino Real San Diego, CA 92130 ... News and Insights. Press Releases; Insights; Investors; Menu Menu; CONTACT. Halozyme Therapeutics. Halozyme Therapeutics 12390 El Camino Real San Diego, CA 92130 Phone: 858.794.8889 Fax: 858.704.8311 Email: [email protected]. WebFeb 2, 2024 · Halozyme Appoints New Chief Financial Officer. News provided by. Halozyme Therapeutics, Inc. Feb 02, 2024, 16:43 ET. SAN DIEGO, Feb. 2, 2024 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ ...
WebAug 16, 2024 · SAN DIEGO, Aug. 15, 2024 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme" or the "Company"), a leader in converting IV biologics to subcutaneous delivery, today announced the ...
WebApr 13, 2024 · In other Halozyme Therapeutics news, CFO Nicole Labrosse sold 2,525 shares of the company's stock in a transaction that occurred on Thursday, February … boc and fmocWebMar 20, 2024 · The firm has a market cap of $4.48 billion, a PE ratio of 22.81, a price-to-earnings-growth ratio of 0.47 and a beta of 1.26. Halozyme Therapeutics has a twelve month low of $32.93 and a twelve month high of $59.46. Insider Buying and Selling. In other Halozyme Therapeutics news, CEO Helen Torley the SEC website. In other news, … boc and brunchWebApr 6, 2024 · Halozyme Therapeutics Non-GAAP EPS of $0.47 misses by $0.02, revenue of $117.3M misses by $10.95M SA News Tue, May 10, 2024 Halozyme Therapeutics … clock eventsWebApr 11, 2024 · Halozyme Therapeutics, Inc. has a 52-week low of $32.83 and a 52-week high of $59.46. Wall Street Analysts Forecast Growth Several research analysts have recently issued reports on the company. boca museum of art miznerWebApr 13, 2024 · SAN DIEGO and EWING, N.J., April 13, 2024 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") and Antares Pharma, Inc. (NASDAQ: ATRS) ("Antares") today announced that the ... boc and iws same companyWeb23 hours ago · Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. … clock evictionWebJan 10, 2024 · 2024 Non-GAAP Diluted EPS Guidance of $2.50 to $2.65 . SAN DIEGO, Jan. 10, 2024 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced its 2024 financial guidance and commented on its outlook for the upcoming year. "In 2024, we project we achieved record revenue of greater than $655 million and we … bo camp wembley